The combination of PD-1/PD-L1 inhibition with blockade of the non-redundant and complementary checkpoint CTLA-4 is backed by strong pre-clinical evidence and has proven very effective in advanced melanoma patients in phase I-III trials, as manifest by rapid, durable responses in a high proportion of patients [26–28]. This evidence concerns the gene CD274 and melanoma.